NCT07437729 Glycocalyx and Oxidative Stress in Endothelial Function (Part 1)
| NCT ID | NCT07437729 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Josip Juraj Strossmayer University of Osijek |
| Condition | Chronic Kidney Disease Patients |
| Study Type | OBSERVATIONAL |
| Enrollment | 105 participants |
| Start Date | 2025-10-01 |
| Primary Completion | 2029-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 105 participants in total. It began in 2025-10-01 with a primary completion date of 2029-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The primary research objective of the project is to determine the role of eGC in microvascular reactivity in CKD (cross-sectional study 1). The main objective of the project is to increase the excellence and interdisciplinarity of scientific work at MEFOS by connecting researchers from different scientific fields, improving conditions and resources for scientific work, and increasing international cooperation, in line with strategic objective 1: raising scientific excellence. The results of the project could provide pathophysiological insight into the development and maintenance of endothelial dysfunction in CKD, as well as identify new biomarkers for CKD.
Eligibility Criteria
Inclusion Criteria: * patients with CKD of hypertensive etiology (grades 1-2 and 3-5; eGFR CKD-EPI GFR ≥ 90 ml/min/1.73 m², i.e. \< 60 mL/min/1.73 m2), non-diabetics, non-smokers * patients with hypertension (according to ESH2023 Guidelines) without kidney damage (eGFR CKD-EPI \>90 mL/min/1.73 m2) non-diabetics, non-smokers * healthy volunteer subjects as controls Exclusion Criteria: * kidney disease of any other etiology except hypertension * endocrine, autoimmune or inflammatory diseases that could affect kidney function. * smoking * diabetes
Contact & Investigator
Ines Drenjančević, MD, PhD
STUDY CHAIR
Faculty of Medicine Josip Juraj Strossmayer University of Osijek
Frequently Asked Questions
Who can join the NCT07437729 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Chronic Kidney Disease Patients. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07437729 currently recruiting?
Yes, NCT07437729 is actively recruiting participants. Contact the research team at ines.drenjancevic@mefos.hr for enrollment information.
Where is the NCT07437729 trial being conducted?
This trial is being conducted at Osijek, Croatia.
Who is sponsoring the NCT07437729 clinical trial?
NCT07437729 is sponsored by Josip Juraj Strossmayer University of Osijek. The principal investigator is Ines Drenjančević, MD, PhD at Faculty of Medicine Josip Juraj Strossmayer University of Osijek. The trial plans to enroll 105 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.